计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
G101480-1mg |
1mg |
现货 ![]() |
| |
G101480-5mg |
5mg |
现货 ![]() |
| |
G101480-25mg |
25mg |
现货 ![]() |
| |
G101480-100mg |
100mg |
现货 ![]() |
| |
G101480-250mg |
250mg |
现货 ![]() |
|
别名 | 藤黄酸 A | R,S-藤黄酸 |
---|---|
英文别名 | Cambogic acid | H10129 | B''-Guttiferin | CCG-270284 | 1,5-Methano-1H,3H,11H-furo(3,4-g)pyrano(3,2-b)xanthene-1-crotonic acid, 3a,4,5,7-tetrahydro-8-hydroxy-alpha,3,3,11-tetramethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-, (Z)- | GEZH |
规格或纯度 | ≥97%(HPLC) |
英文名称 | Gambogic acid |
生化机理 | 甘宝酸是一种黄酮类化合物,提取自加纳藤的褐色或橙色树脂。这种天然化学物质在小鼠临床试验中显示出良好的抗肿瘤活性。甘草酸激活 Caspases 的 EC50 为 0.78-1.64 μM,竞争性抑制 Bcl-xl、Bcl-2、Bcl-w、Bcl-B、Bfl-1 和 Mcl-1,IC50 分别为 1.47 μM、1.21 μM、2.02 μM、0.66 μM、1.06 μM 和 0.79 μM。甘草酸是一种 caspase 激活剂和细胞凋亡诱导剂,可使细胞周期的 G2/M 阶段发生不可逆的停滞。细胞凋亡剂。降低 Bcl-2 表达,增加 Bax 表达。增强顺铂诱导的细胞凋亡。抑制血管生成。在体内显示抗肿瘤作用。口服有效。 |
应用 | 藤黄酸作为蛋白酶激活和凋亡诱导剂,会捕获细胞周期的G2 / M期,而且造成不可逆。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。有毒,请参阅SDS以获取更多信息。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
产品介绍 |
不溶于水藤黄酸作为蛋白酶激活和凋亡诱导剂,会捕获细胞周期的G2 / M期,而且造成不可逆。 Gambogic acid causes an irreversible arrest in the G2/M phase of the cell cycle. It acts as a caspase activator and apoptosis inducer |
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504764974 |
---|---|
分子类型 | 小分子 |
IUPAC Name | (Z)-4-[(1S,2S,8R,17S,19R)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid |
INCHI | InChI=1S/C38H44O8/c1-20(2)10-9-15-36(8)16-14-24-29(39)28-30(40)26-18-23-19-27-35(6,7)46-37(33(23)41,17-13-22(5)34(42)43)38(26,27)45-32(28)25(31(24)44-36)12-11-21(3)4/h10-11,13-14,16,18,23,27,39H,9,12,15,17,19H2,1-8H3,(H,42,43)/b22-13-/t23-,27+,36-,37+,38-/m1/s1 |
InChi Key | GEZHEQNLKAOMCA-RRZNCOCZSA-N |
Canonical SMILES | CC(=CCCC1(C=CC2=C(C3=C(C(=C2O1)CC=C(C)C)OC45C6CC(C=C4C3=O)C(=O)C5(OC6(C)C)CC=C(C)C(=O)O)O)C)C |
Isomeric SMILES | CC(=CCC[C@@]1(C=CC2=C(C3=C(C(=C2O1)CC=C(C)C)O[C@@]45[C@H]6C[C@@H](C=C4C3=O)C(=O)[C@@]5(OC6(C)C)C/C=C(/C)\C(=O)O)O)C)C |
WGK Germany | 1 |
RTECS | PB9268200 |
PubChem CID | 9852185 |
UN Number | 1356 |
分子量 | 628.75 |
溶解性 | DMSO: ≥100 mg/mL;H2O: insoluble;Ethanol:100 mg/mL |
---|---|
密度 | 1.29 |
沸点 | 280°C |
熔点 | 81.8°C |
分子量 | 628.700 g/mol |
XLogP3 | 7.300 |
氢键供体数Hydrogen Bond Donor Count | 2 |
氢键受体数Hydrogen Bond Acceptor Count | 8 |
可旋转键计数Rotatable Bond Count | 8 |
精确质量Exact Mass | 628.304 Da |
单同位素质量Monoisotopic Mass | 628.304 Da |
拓扑极表面积Topological Polar Surface Area | 119.000 Ų |
重原子数Heavy Atom Count | 46 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 1490.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 5 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 1 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
象形图 | GHS06, GHS07 |
---|---|
信号词 | Danger |
危险声明 |
H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 H301: 吞咽会中毒 |
预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P302+P352: 如皮肤沾染:用水充分清洗。 P321: 特殊处理(请参阅此标签上的...)。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P264: 处理后要彻底洗手。 P271: 仅在室外或通风良好的地方使用。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P304+P340: 如误吸入:将人转移到空气新鲜处,保持呼吸舒适体位。 P403+P233: 存放在通风良好的地方。保持容器密闭。 P362+P364: 脱掉沾污的衣服,清洗后方可重新使用。 P330: 漱口 P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。 P301+P316: 如果吞咽:立即寻求紧急医疗救助。 P337+P317: 如果眼睛刺激持续:寻求医疗帮助。 P332+P317: 如果出现皮肤刺激:请寻求医疗帮助。 P319: 如果你感到不适,请寻求医疗帮助。 |
WGK Germany | 1 |
RTECS | PB9268200 |
个人防护装备 | Eyeshields,Faceshields,Gloves,type P2 (EN 143) respirator cartridges |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 25-02-08 | G101480 |
![]() |
分析证书 | 25-02-08 | G101480 |
![]() |
分析证书 | 24-07-10 | G101480 |
![]() |
分析证书 | 24-07-10 | G101480 |
![]() |
分析证书 | 24-07-10 | G101480 |
![]() |
分析证书 | 24-07-10 | G101480 |
![]() |
分析证书 | 24-07-10 | G101480 |
![]() |
分析证书 | 24-07-10 | G101480 |
![]() |
分析证书 | 24-07-10 | G101480 |
![]() |
分析证书 | 23-12-21 | G101480 |
![]() |
分析证书 | 23-12-21 | G101480 |
![]() |
分析证书 | 23-12-21 | G101480 |
![]() |
分析证书 | 21-11-01 | G101480 |
![]() |
分析证书 | 21-11-01 | G101480 |
¥439.90
1. Dinghu Zhang, Yanhong Chu, Hanqing Qian, Lingyu Qian, Jie Shao, Qiuping Xu, Lixia Yu, Rutian Li, Quanan Zhang, Fenglei Wu, Baorui Liu, Qin Liu. (2023) Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer. International Journal of Nanomedicine, [PMID:32099362] [10.2147/IJN.S231448] |
2. Lili Qian, Qian Li, Zhenshan Ding, Kejun Luo, Jiamin Su, Jiawei Chen, Guangying Zhu, Zhihua Gan, Qingsong Yu. (2022) Prodrug Nanosensitizer Overcomes the Radiation Resistance of Hypoxic Tumor. ACS Applied Materials & Interfaces, 14 (51): (56454–56470). [PMID:36525559] [10.1021/acsami.2c14628] |
3. Yuhan Wang, Chunyan Yue, Mengyao Zhang, Dazhao Li, Tao Xu, Mengying He, Mengyuan Wang, Yanan Zhao, Zihui Ni, Feng Zhi, Yiqiao Hu, Dawei Ding. (2023) Dually enhanced phototherapy by gambogic acid and hyperthemia-activated chemotherapy for synergistic breast cancer treatment. CHEMICAL ENGINEERING JOURNAL, 452 (139108). [10.1016/j.cej.2022.139108] |
4. Shu-Ting Xu, Cheng Yang, Xiu-Ping Yan. (2021) Nanothorn Filter-Facilitated Online Cell Lysis for Rapid and Deep Intracellular Profiling by Single-Cell Mass Spectrometry. ANALYTICAL CHEMISTRY, 93 (47): (15677–15686). [PMID:34784185] [10.1021/acs.analchem.1c03529] |
5. Lulu Cai, Lina Dong, Xuan Sha, Shuai Zhang, Siwen Liu, Xiaoxi Song, Mingming Zhao, Qi Wang, Kai Xu, Jingjing Li. (2021) Exfoliation and in situ functionalization of MoS2 nanosheets for MRI-guided combined low-temperature photothermal therapy and chemotherapy. MATERIALS & DESIGN, 210 (110020). [10.1016/j.matdes.2021.110020] |
6. Zhang Gutian, Cheng Wenting, Du Lin, Xu Chuanjun, Li Jinlong. (2021) Synergy of hypoxia relief and heat shock protein inhibition for phototherapy enhancement. JOURNAL OF NANOBIOTECHNOLOGY, 19 (1): (1-13). [PMID:33407570] [10.1186/s12951-020-00749-5] |
7. Chen Jun, Li Lihua, Zhou Yun, Zhang Jiahua, Chen Lei. (2021) Gambogic acid ameliorates high glucose– and palmitic acid–induced inflammatory response in ARPE-19 cells via activating Nrf2 signaling pathway: ex vivo. CELL STRESS & CHAPERONES, 26 (2): (367-375). [PMID:33245515] [10.1007/s12192-020-01182-1] |
8. Jinghua Li, Daoming Zhu, Weijie Ma, Yang Yang, Ganggang Wang, Xiaoling Wu, Kunlei Wang, Yiran Chen, Fubing Wang, Wei Liu, Yufeng Yuan. (2020) Rapid synthesis of a Bi@ZIF-8 composite nanomaterial as a near-infrared-II (NIR-II) photothermal agent for the low-temperature photothermal therapy of hepatocellular carcinoma. Nanoscale, 12 (32): (17064-17073). [PMID:32785323] [10.1039/D0NR03907A] |
9. Dinghu Zhang, Zhengyun Zou, Wei Ren, Hanqing Qian, Qianfeng Cheng, Liulian Ji, Baorui Liu, Qin Liu. (2018) Gambogic acid-loaded PEG–PCL nanoparticles act as an effective antitumor agent against gastric cancer. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 23 (1): (33-40). [PMID:29069711] [10.1080/10837450.2017.1295068] |
1. Adler D et al.. (2021) Weak Electromagnetic Fields Accelerate Fusion of Myoblasts.. Int J Mol Sci, 22 (9): [PMID:33922487] |
2. Dinghu Zhang, Yanhong Chu, Hanqing Qian, Lingyu Qian, Jie Shao, Qiuping Xu, Lixia Yu, Rutian Li, Quanan Zhang, Fenglei Wu, Baorui Liu, Qin Liu. (2023) Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer. International Journal of Nanomedicine, [PMID:32099362] [10.2147/IJN.S231448] |
3. Lili Qian, Qian Li, Zhenshan Ding, Kejun Luo, Jiamin Su, Jiawei Chen, Guangying Zhu, Zhihua Gan, Qingsong Yu. (2022) Prodrug Nanosensitizer Overcomes the Radiation Resistance of Hypoxic Tumor. ACS Applied Materials & Interfaces, 14 (51): (56454–56470). [PMID:36525559] [10.1021/acsami.2c14628] |
4. Yuhan Wang, Chunyan Yue, Mengyao Zhang, Dazhao Li, Tao Xu, Mengying He, Mengyuan Wang, Yanan Zhao, Zihui Ni, Feng Zhi, Yiqiao Hu, Dawei Ding. (2023) Dually enhanced phototherapy by gambogic acid and hyperthemia-activated chemotherapy for synergistic breast cancer treatment. CHEMICAL ENGINEERING JOURNAL, 452 (139108). [10.1016/j.cej.2022.139108] |
5. Shu-Ting Xu, Cheng Yang, Xiu-Ping Yan. (2021) Nanothorn Filter-Facilitated Online Cell Lysis for Rapid and Deep Intracellular Profiling by Single-Cell Mass Spectrometry. ANALYTICAL CHEMISTRY, 93 (47): (15677–15686). [PMID:34784185] [10.1021/acs.analchem.1c03529] |
6. Lulu Cai, Lina Dong, Xuan Sha, Shuai Zhang, Siwen Liu, Xiaoxi Song, Mingming Zhao, Qi Wang, Kai Xu, Jingjing Li. (2021) Exfoliation and in situ functionalization of MoS2 nanosheets for MRI-guided combined low-temperature photothermal therapy and chemotherapy. MATERIALS & DESIGN, 210 (110020). [10.1016/j.matdes.2021.110020] |
7. Zhang Gutian, Cheng Wenting, Du Lin, Xu Chuanjun, Li Jinlong. (2021) Synergy of hypoxia relief and heat shock protein inhibition for phototherapy enhancement. JOURNAL OF NANOBIOTECHNOLOGY, 19 (1): (1-13). [PMID:33407570] [10.1186/s12951-020-00749-5] |
8. Chen Jun, Li Lihua, Zhou Yun, Zhang Jiahua, Chen Lei. (2021) Gambogic acid ameliorates high glucose– and palmitic acid–induced inflammatory response in ARPE-19 cells via activating Nrf2 signaling pathway: ex vivo. CELL STRESS & CHAPERONES, 26 (2): (367-375). [PMID:33245515] [10.1007/s12192-020-01182-1] |
9. Jinghua Li, Daoming Zhu, Weijie Ma, Yang Yang, Ganggang Wang, Xiaoling Wu, Kunlei Wang, Yiran Chen, Fubing Wang, Wei Liu, Yufeng Yuan. (2020) Rapid synthesis of a Bi@ZIF-8 composite nanomaterial as a near-infrared-II (NIR-II) photothermal agent for the low-temperature photothermal therapy of hepatocellular carcinoma. Nanoscale, 12 (32): (17064-17073). [PMID:32785323] [10.1039/D0NR03907A] |
10. Dinghu Zhang, Zhengyun Zou, Wei Ren, Hanqing Qian, Qianfeng Cheng, Liulian Ji, Baorui Liu, Qin Liu. (2018) Gambogic acid-loaded PEG–PCL nanoparticles act as an effective antitumor agent against gastric cancer. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 23 (1): (33-40). [PMID:29069711] [10.1080/10837450.2017.1295068] |